Old abstract concerning biomarkers for AD that was the basis for the PR to which this post is linked:
>>DIAGNOSTIC BIOMARKERS OF ALZHEIMER S DISEASE IN HUMAN CSF.
A.H.Simonsen1; H.Davies1; K.Blennow3; E.T.Fung1*
1. Biomarker Discovery Ctr., Ciphergen Biosystems, Copenhagen, Denmark
2. Biomarker Discovery Ctr., Ciphergen Biosystems, Copenhagen, Denmark
3. Clin. Neurosci., Sahlgren's Univ. Hosp., Molndal, Sweden
Alzheimers disease (AD) is the most common form of dementia found in all human populations worldwide. AD can only be diagnosed conclusively by examining the brain after death to determine the levels of plaques and tangles in certain brain regions. Early diagnosis of probable or possible AD through clinical evaluation of cognitive function has been shown to result in a misdiagnosis rate of 10-20% following post-mortem examination of brain pathology. New biomarkers for early and specific diagnosis of AD are needed to achieve greater insight into changes occurring in the brain and direct therapeutic strategies. Given that no one pathological process is specific for AD it seems unlikely that a single biochemical marker could discriminate between AD and other dementias. In this study, a multi-marker pattern generating approach was taken using Surface Enhanced Laser Desorption/Ionization (SELDI) TOF-MS detection from Ciphergen Biosystems Inc to profile 30 probable AD cases vs. 35 age matched normal individuals. Probable AD phenotype was previously determined using existing CSF biochemical markers (T-Tau, P-Tau and A-beta 1-42 levels), mental scoring (MMSE) and genetic predisposition (ApoE genotype). Using three anion-exchange fractions and three array surface types (weak cation exchange, immobilized metal affinity capture and hydrophobic) 39 candidate biomarkers were found with P values< 0.0001. A four peak pattern of markers was able to correctly group 30 out of 30 AD samples and 33 out of 35 age matched normal individuals. Work is ongoing to further validate these markers through screening of separate cohorts of human CSF samples.Conflict of Interest: Three authors are employees of Ciphergen Biosystems.
Citation:
A.H. Simonsen, H. Davies, K. Blennow, E.T. Fung. DIAGNOSTIC BIOMARKERS OF ALZHEIMER S DISEASE IN HUMAN CSF. Program No. 134.2. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2003. <<
Cheers, Tuck |
